Incytevs.Moderna
INCY vs MRNA · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Moderna is about 3.9× larger than Incyte by market cap; year to date, Moderna leads (+568.0% vs +14.2%).
Side by side
| INCY | MRNA | |
|---|---|---|
| Market cap | $22.9B | $88.6B |
| Price | $112.79 | $225.00 |
| Today | +0.0% | +14.2% |
| Return YTD | +14.2% | +568.0% |
| Return 1Y | +32.1% | +605.6% |
| Since June 26, 2026 | −0.8% | +234.5% |
| P/E | 14.2 | — |
| P/S | 3.9 | 39.8 |
| P/B | 3.6 | 13.1 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →ModernaMRNA
Built on mRNA, the technology behind its covid vaccine. The pipeline pushes the same platform into further vaccines and into oncology.
Full MRNA profile →More INCY & MRNA comparisons
Other head-to-heads in the Biotech & innovation segment.
See where INCY and MRNA sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →